Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.49 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.43 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.43 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.43 |
| ▸ | NPY4R | P50391 | 11/20 | 0.42 |
| ▸ | NPY1R | P25929 | 6/20 | 0.42 |
| ▸ | NPY2R | P49146 | 4/20 | 0.42 |
| ▸ | NPY5R | Q15761 | 4/20 | 0.42 |
| ▸ | RRM1 | P23921 | 1/20 | 0.41 |
| ▸ | SLC15A1 | P46059 | 1/20 | 0.38 |
| ▸ | OTC | P00480 | 1/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15165702 | 1.00 | DPP7 (0.49) | DPP7GNAI3GNAO1GNAI1NPY4R | |
| SCHEMBL1388277 | 1.00 | DPP7 (0.49) | DPP7GNAI3GNAO1GNAI1NPY4R | |
| SCHEMBL17525174 | 0.95 | DPP7 (0.51) | DPP7GNAI3GNAO1GNAI1NPY4R | |
| SCHEMBL13319577 | 0.86 | DPP7 (0.49) | DPP7GNAI3GNAO1GNAI1NPY4R | |
| SCHEMBL14769718 | 0.86 | DPP7 (0.49) | DPP7GNAI3GNAO1GNAI1NPY4R | |
| SCHEMBL15627730 | 0.86 | DPP7 (0.46) | DPP7GNAI3GNAO1GNAI1NPY4R | |
| SCHEMBL23610947 | 0.86 | DPP7 (0.61) | DPP7GNAI3GNAO1GNAI1NPY4R | |
| SCHEMBL15165700 | 0.86 | DPP7 (0.51) | DPP7GNAI3GNAO1GNAI1RRM1 | |
| SCHEMBL23626315 | 0.86 | DPP7 (0.61) | DPP7GNAI3GNAO1GNAI1NPY4R | |
| SCHEMBL30483974 | 0.85 | NPY4R (0.53) | DPP7GNAI3GNAO1GNAI1NPY4R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4720058-A2 | BIFUNCTIONAL DEGRADERS AND USES THEREOF | Casma Therapeutics, Inc. (US) | 2026-04-08 | — | — | EP | disclosed |
| WO-2024249291-A2 | BIFUNCTIONAL DEGRADERS AND USES THEREOF | CASMA THERAPEUTICS, INC. (US) | 2024-12-05 | — | — | WO | disclosed |
| WO-2024147125-A1 | CYCLOBUTYL-SUBSTITUTED PHENOXY-DIOXETANES AND USES THEREOF | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2024-07-11 | — | — | WO | disclosed |
| EP-4219717-A2 | EXON SKIPPING OLIGOMERS FOR MUSCULAR DYSTROPHY | Sarepta Therapeutics, Inc. (US) | 2023-08-02 | — | — | EP | disclosed |
| US-20220193246-A1 | COMPOSITIONS FOR TREATING MUSCULAR DYSTROPHY | SAREPTA THERAPEUTICS, INC. (US) | 2022-06-23 | — | — | US | disclosed |
| US-10765760-B2 | Exon skipping oligomer conjugates for muscular dystrophy | SAREPTA THERAPEUTICS, INC. (US) | 2020-09-08 | — | — | US | disclosed |
| US-10758629-B2 | Exon skipping oligomer conjugates for muscular dystrophy | SAREPTA THERAPEUTICS, INC. (US) | 2020-09-01 | — | — | US | disclosed |
| WO-2020023688-A1 | EXON SKIPPING OLIGOMERS FOR MUSCULAR DYSTROPHY | SAREPTA THERAPEUTICS, INC. (US) | 2020-01-30 | — | — | WO | disclosed |
| US-20180200286-A1 | METHODS AND COMPOSITIONS FOR TREATING WOUNDS UTILIZING CHITOSAN COMPOUNDS | UNITED STATES GOVERNMENT | 2018-07-19 | — | — | US | disclosed |
| EP-2391636-B1 | ANTIBIOTIC PEPTIDES | AMP-THERAPEUTICS GMBH (DE) | 2017-09-27 | — | — | EP | disclosed |
| US-20170119810-A1 | METHODS AND COMPOSITIONS FOR TREATING WOUNDS UTILIZING CHITOSAN COMPOUNDS | UNITED STATES GOVERNMENT | 2017-05-04 | — | — | US | disclosed |
| WO-2012122422-A2 | ACTIVE AGENT PRODRUGS WITH HETEROCYCLIC LINKERS | SIGNATURE THERAPEUTICS, INC. (US) | 2012-09-13 | — | — | WO | disclosed |
| EP-0680469-B1 | AMINOACID DERIVATES, MEDICAMENTS CONTAINING THESE COMPOUNDS AND PROCESS FOR PREPARING THE SAME | BOEHRINGER INGELHEIM PHARMA (DE) | 2000-04-26 | — | — | EP | disclosed |
| WO-1992007568-A1 | η-TURN PEPTIDOMIMETICS AS FIBRINOGEN ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1992-05-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220193246-A1 | COMPOSITIONS FOR TREATING MUSCULAR DYSTROPHY | UTRN, EDNRA, MTPN | DPP7 2283/4885GNAI3 1241/4885GNAO1 1905/4885 |
| US-10765760-B2 | Exon skipping oligomer conjugates for muscular dystrophy | SMN1; SMN2, UTRN, RBM17 | DPP7 1299/4885GNAI3 3246/4885GNAO1 2566/4885 |
| US-20180200286-A1 | METHODS AND COMPOSITIONS FOR TREATING WOUNDS UTILIZING CHITOSAN COMPOUNDS | CHIA, MMP8, CHIT1 | DPP7 550/4885GNAI3 3143/4885GNAO1 3506/4885 |
| US-10758629-B2 | Exon skipping oligomer conjugates for muscular dystrophy | UTRN, SMN1; SMN2, RBM17 | DPP7 1325/4885GNAI3 3169/4885GNAO1 2522/4885 |
| US-20170119810-A1 | METHODS AND COMPOSITIONS FOR TREATING WOUNDS UTILIZING CHITOSAN COMPOUNDS | CHIA, MMP8, CHIT1 | DPP7 550/4885GNAI3 3143/4885GNAO1 3506/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.